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The College of Veterinary Medicine, despite reduced state funding, has enjoyed another good year of scholarship. 
Our success can be greatly attributed to the flexibility this Center offers in supporting the best and most productive 
programs. 
While a full search for an assistant/associate dean for research and graduate programs was completed this year, the 
College elected to forego filling the position for now. This decision was based on two major criteria: the current 
fiscal climate in higher education and information gathered during the search. In the interviewing process, it was 
recognized that while modestly funded, we have a firm research foundation and that our College is still recognizing 
growth. It was clear from our discussions with all the candidates that we distribute funds fairly and in a clearly 
identified manner. Moreover, the excellent scientific recommendations provided by both the external and internal 
advisory committees, coupled with the spirit of cooperation and commitment to quality fostered by the Center's 
administrators has, even in these fmancially troubled times, maintained excellent progress toward Center goals. 
In view of the above fmdings, we feel that additional leadership in research and graduate programs, while desired, is 
not yet essential. The College is in the process of hiring a grants and contracts specialists to better oversee the 
research funds. 
This report documents the success from careful management of COE funding. However, much scholarship is an 
indirect result of COE. For example, because of our successive growth, we are able to attract young researchers such 
as Dr. Steve Kania who comes to the College with his own funding. His grant entitled "Identification of C3 binding 
components that facilitate invasion by Bahesia bigemia" is through the USDA His research intertwines well with Dr. 
Leon Potgieter's and our effort in livestock diseases and population medicine. 
Other excellent examples of how instrumental COE funds are to the College are: 
• 	 Dr. S. Orosz's project entitled "Evaluation of the pharmacokinetic disposition if Itraconzaole in Blue Fronted 
Amazon Parrots" was funded by the Association of Avian Veterinarians. Preliminary data secured with COE 
funds allowed her grant to be competitive enough to receive the funding. 
• 	 Dr. Rhea Morgan, a new faculty member, was able to capitalize on her COE seed monies by gaining funds 
from Schering-Plough Animal Health to "determine the effectiveness of cyc1osporine ophthalmic ointment in 
dog." 
As the College advances, COE funds will continue to be counted on to challenge excellence and reward diligence and 
dedication as we stay focused on our goals to maintain that cutting edge -- to strive for continual growth. These 
funds also provide much needed funding for some exposure to research as a career choice for some of our students. 
Sincerely, 
~~fL 
vjb 
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1 Programmatic Report 
I. PROGRAMMATIC REPORT 
LA. REASSIGNMENT OF CENTER FACULTY 
One of the four major research groups, Oncology, has been divided into two 
groups. 
One of DR. H. SCHULLER'S accomplishments this year, has been to establish 
the "Carcinogenesis and Developmental Therapeutics (CDT) Program." This 
program, directed by DR. SCHULLER, brings together basic cancer researchers and 
clinical oncologists to provide an incentive for interactive disciplinary collaborations 
and a forum for guidance and assistance of junior faculty in obtaining outside funds. 
Currently, active members of this program include: DRS. K. HAHN and A. Legendre 
(clinical veterinary oncology), T. Panella (human clinical oncology), D. McGavin 
(pathology), M. MILLER (molecular biology), and H. M. SCHULLER (experimental 
oncology). As an initial success of this program, DR. SCHULLER was able to obtain a 
contract with a pharmaceutical company for DR. K. HAHN, for a 2-year clinical trial in 
dogs with osteosarcomas. It is anticipated that this study will provide convincing 
preliminary data useful for the generation of larger grant funds in this area. 
Under the direction of DR. T. SCHULTZ, the "In Vitro Toxicology and 
Toxicokinetics (IVTT) Group" is comprised of DR. SCHULTZ, DR. D. L. FRAZIER, DR. T. 
ROWLES, and Dr. D. Ward. The newly formed program will attempt to carve out a 
niche in the vast arena of toxicology by building on the strengths and interests of 
existing CVM faculty. DR. T. SCHULTZ brings to the group his long-standing interest 
in in vitro toxicity testing, structure-activity, and microscopy. DR. T. ROWLES brings 
her interest and expertise in mammalian cell/tissue culture techniques and 
neurotoXICIty. DR. D. FRAZIER brings to the group her interest and expertise in 
biocheInistry and toxicokinetics. The initial focus of the groups will be on 
neurotoxicity. The basic research efforts will be aimed at elucidating the 
mechanisms of neurotoxic action. Specifically, the group will collaborate on the 
development, validation and use of a novel, complex co-culture system of 
endothelial, neuronal and neuroglia cells as an in vitro tool with which to model the 
blood-brain barrier (BBB) and its relationship to neurotoxicity. This model will 
provide a basis for studies investigating BBB transport and cytotoxicity induced by 
other photosensitizing drugs. This program will use as it spring boards the 
cooperative agreement with USEP A currently being finalized by DR. T. ROWLES. 
These new groups will be structured into the preexisting Growth Factors 
Group, Infectious Diseases and Population Medicine Group, and the Inflammation 
and Host Defense Group. 
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I.B. PERSONNEL CHANGES 
1.B.1. Personnel Additions 
DR. KEVIN HAHN Joms the "Carcinogenesis and Developmental 
Therapeutics (CDT) Program." He received both his D.V.M. and Ph.D. from 
Purdue University. 
1.B.2. Personnel Deletions 
DR. MICHAEL BREIDER joined Parke-Davis Pharmaceuticals in Ann 
Arbor, Michigan, on January 1, 1993. 
DR. DOUG DAWSON leaves the college on June 30, 1993, to accept a 
faculty position with Ashland University in Ashland, Ohio. 
I.e. CENTER GOALS 
Goal 1: To IMPROVE THE QUALI1Y OF HUMAN LIFE THROUGH BETfER ANIMAL HEALTH. 
DR. L. MUNSON made significant progress in understanding the role of 
transforming growth factor-Bs in the development of the bovine placenta. She and 
her laboratory have determined that TGF-f3s 1-3 promote proliferation of bovine 
trophoblastic and endometrial epithelial cells in culture. They also have found that 
this atypical action of TGF-f3 may be due to synergism with platelet-derived growth 
factors (PDGF). PDGF-af3 is a potent mitogen for their bovine placental and 
endometrial cell line and for two primary human endometrial epithelial cell lines 
they developed from tissues obtained in collaboration with Drs. Nirmali B. 
Upadhyaya and Stuart Van Meter for the UTK Medical Center. She has also 
determined through collaboration with DR. J. GODKIN that TGF-f3 is synergistic with 
retinoic acid, a substance that also regulate PDGF transcription. 
Research performed in DR. J. GODKIN'S laboratory focuses on fetal-maternal 
interactions that contribute to the maintenance of pregnancy and growth and 
development of the embryo in domestic farm animals. Their efforts have been 
concentrated on proteins produced by the blastocyst, extraembryonic placental 
membranes and the maternal uterus. The conceptus interferon (INF) tau (7), 
formerly called trophoblast protein-l and acknowledged to be the embryonic signal 
for early pregnancy maintenance, was demonstrated to diminish uterine cell 
prostaglandin (PG) production in vitro. Additionally, interferon 7 inhibited oxytocin 
stimulation of uterine cell PG production, illustrating that INF7 maintains early 
pregnancy by preventing production of PGF2a, the uterine luteolysin, which causes 
the regression of the corpus luteum in cyclic animals. Vitamin A (retinol) is 
essential for reproduction and retinoic acid, a natural metabolite of vitamin A, is 
believed to be the morphogen that dictates pattern formation in developing 
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embryos. They have demonstrated that retinol-binding protein (RBP), the retinol 
transport protein, is a product of all extraembryonic placental membranes and the 
maternal uterus. Embryonic cell growth, differentiation and cell migration are 
believed to be influenced by both humoral factors (such as growth factors and 
retinoids) and interaction with the extracellular matrix. It is anticipated that this 
project will receive major extramural funding next year. Recently, they have 
isolated from placental membrane cultures, a secreted precursor of collagen, an 
extracellular matrix protein. This protein has been cloned and sequenced. Currently 
studies are examining the role of humoral factors in collagen expression in placental 
and uterine cells and the influence of this collagen on cell behavior. 
Goal 2: 	 To AUGMENT LIVESTOCK DISEASE RESEARCH CAPABILmES IN THE INSTITUTE OF 

AGRICULTURE. 

In DR. D. SlAUSON'S studies on the mechanisms of interaction of endotoxin 
(LPS) with target cells, his laboratory found that LPS-induced procoagulant activity 
in bovine lung macrophages was dependent on the important intracellular signalling 
kinase, protein kinase-Co In more recent studies, they have expanded on this initial 
finding and have obtained evidence that the proximal signalling pathway may involve a 
G-protein-linked receptor as well. This G-protein-linked receptor appears to initiate 
signalling through a pathway that may not involve mobilization of Ca2+. 
Additionally, recent research has clearly established the presence and a role for 
bovine lipopolysaccharide binding protein (LBP) in the interaction of LPS with 
crucial target cells. They are continuing to follow these leads regarding the 
transmembrane signalling pathways used by LPS and LPS/LBP complexes in bovine 
lung macrophages. 
DR. P. BOCHSLER has spent the year purifying and characterizing bovine 
lipopolysaccharide-binding protein. He has identified the bovine CD14 receptor 
(LBP) and has characterized the response of bovine endothelial cells to endotoxin. 
Further, he has characterized the signal transduction in bovine endothelial cells in 
response to endotoxin or other stimuli. He is also collaborating on elucidation of 
endotoxin-mediated signal transduction pathways in bovine macrophages with DR. 
D. SlAUSON. 
Goal 3: 	To IDENTIFY AND CHARACfERIZE ANIMAL DISEASES THAT ARE ANALOGOUS TO HUMAN 

DISEASES. 

DR. R. SHULL studied the retroviral vector constructs LCldSN and LHIdSN in 
canine marrow cultures and fibroblasts. Marrow cells from 
Mucopolysaccharidosis I (MPS I)-affected dogs were infected by vector containing 
2 
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supernatant in liquid culture on autologous, pre-established stromal layers. Non­
adherent cells from liquid cultures produced iduronidase for ZO days at levels 
approximately twice that of endogenous iduronidase in similarly cultured cells from 
unaffected dogs. Fibroblasts from an affected dog and a normal control were 
similarly transfected with LCldSN. Iduronidase production transfected MPS I 
fibroblasts was Z-10 times that of normal dog fibroblasts over a period of 50 days in 
culture. 
DR. D. DAWSON, in conjunction with DR. T. SCHULTZ, has spent this year 
evaluating malformation of Xenopus embryos exposed to selected short-chain 
carboxylic acids. Valproic acid is a known human teratogen which causes 
malformation of the central nervous system. This acid has been tested in an effort 
to determine the structural requirement for the induction of malformation. They 
have found that while branching effects metabolism, it is the presence of a 5- or 6­
carbon chain that is important for teratogenesis. 
DR. T. SCHULTZ is embarking on the third year of a three-year project entitled 
"Predictive Toxicities of Selected Oxygen-containing Molecules." The project 
centers on examining the toxicity of oxygen-containing aliphatic and aromatic 
industrial chemicals specifically alcohols, aldehydes, and esters. Specific aims 
concerning toxicity testing and modeling of direct-acting bioreactive aldehydes, have 
been completed this past year. This work has shown that testing protocol are directly 
correlated with toxicity and the toxicity of aldelydes cannot be extrapolated from one 
species to another. Moreover, the test of unsaturated aliphatic alcohols, was also 
completed during the year. Results on the relative toxicity ofpropargylic alcohols has 
shown these alpha-beta unsaturated alcohols are metabolized to highly toxic ketenes. 
Leydig cells in the testis interstitium are the primary source of testosterone in 
the adult male mammal. In the steroid synthetic pathway, cholesterol, which is an 
obligatory intermediate, needs to be transported into mitochondria to initiate this 
process. Despite the vast amount of research conducted on aspects of steroid 
hormone biosynthesis in many tissues (such a adrenal, ovary, testis) the mechanism 
of cholesterol transport into the inner mitochondrial membrane is poorly 
understood. As cholesterol is highly insoluble in water and cannot freely diffuse 
within the Leydig cells, existence of a carrier mechanism to perform this function is 
speculated. It is known that in liver and adrenal gland sterol carrier protein-Z 
(SCPZ), a 14 kDa protein is involved in this carrier mechanism. DR. C. MENDIS­
lIANDAGAMA'S previous studies have shown that SCP2 is highly concentrated in 
peroxisomes in Leydig cells and that intraperoisomal SCP2 content is regulated by 
luteinizing hormone (LH), which stimulates steroid hormone production by Leydig 
cells. During the past year, her research efforts have been to carry out preliminary 
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studies to investigate the mechanism of cholesterol transport during steroid 
hormone biosynthesis in Leydig cells in the testis in response to LH stimulation. 
Goal 4: To STUDY ANIMAL MODELS FOR BETrER UNDERSfANDING OF HUMAN DISEASE. 
Over the past year, DR. B. ROUSE has succeeded in providing further evidence 
in support of the hypothesis that stromal keratitis resulting from Herpes simplex virus 
represents an immunopathological reaction mediated by CD4 + T lymphocytes. Their 
new data indicate that a single phenotype of CD4 + T cells, the Th 1 phenotype, is 
involved in the lesions and that such cells might mediate pathology following their 
recognition of a host heat shock protein. Dr. Rouse will also evaluate the ability of 
recombinant attenuated Salmonella that express genes of Herpes simplex virus 
(HSV) to induce protective immunity against viral challenge in animal model 
systems. Special emphasis will be directed at the cytotoxic T lymphocyte response 
since it is hypothesized that for solid immunity to HSV this form of immunity must 
be included in the immune response. His research will evaluate if a recombinant 
attenuated Salmonella vector system hold promise as a means of vaccinating against 
HSVinman. 
DR. H. SCHULLER'S research programs in the area of lung carcinogenesis and 
therapeutics and in the field of transplacental carcinogenesis have continued to 
flourish, resulting in an impressive number of publications and presentations. 
Among the highlights to Dr. Schuller's work was the discovery that certain 
carcinogenic nitrosamines interact with specific signal transduction pathways in selected 
cell types thus resulting in continuous cell proliferation leading to cancer. This work 
has now generated a new grant with the National Cancer Institute for a period of 5 
years. Moreover, Dr. Schuller's research in hamsters has shown, for the first time, that 
in utero exposure of fetuses to ethanol and tobacco-specific nitrosamines may cause a 
high incidence ofpancreas cancer in the offspring. 
Another research project was to adapt the polymerase chain reaction 
technique to amplify small quantities of DNA from paraffin-embedded tissues. DRS. 
M. MILLER and H. SCHULLER have been successful in obtaining amplified sequences of 
the hamster Ki-ras gene. In a recent dose response experiment, areadily detectable 
signal could be obtained by Southern blot analysis of the amplified DNA in less than 
24 hours of autoradiographic exposure from as little as the equivalent of a 1 micron 
piece of tissue from embedded hamster lung samples. This technique should be 
readily adoptable for other gene sequences, and the development of this technique 
in their laboratories should greatly aid their research efforts. These results have 
been used to support NIH grant applications for both investigators. 
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During the past year, DR. E. WILKINSON has made considerable progress in 
characterizing the phenotype of the cells from Tg737 mice that are responsible for 
development of the kidney and liver lesion in this transgenic mouse model of 
autosomal recessive polycystic kidney disease. The morphologic studies of the in 
vivo lesions including the transmission and scanning electron microscopy have been 
completed. Additionally, they have completed the lectin straining for both the liver 
and kidneys. Just recently, they have determined that the Tg737 gene codes for a 
protein with tetratricopeptide repeats. This is the only gene with this structure yet 
identified and characterized in mammalian cells. In lower eucaryootes, a number of 
such genes have been identified and are generally associated with regulation of the 
cell cycle. 
In another collaborative project, DR. B. ROUSE'S laboratory with DR. E. 
WILKINSON'S laboratory will continue and expand their studies of the response of scurfy 
cells to stimulation. Scurfy is an X-linked lymphoproliferative disease of mice that 
results from abnormalities in the development of T cells and depends on the 
genotype of the thymus. In these studies, quantitative mRNA expression, capture 
ELISAs, and ELISA-SPOT analysis will be done on stimulated scurfy and normal T 
cells and purified populations of T cell subsets. These studies should provide 
convincing evidence for any imbalance in Thl and TH2 CD4 + T cells in scurfy. 
Goal 5: 	 To UNDERSrAND THE PATHOGENESIS AND CHARACfERIZE THE CAUSATIVE AGENTS OF 

COMMON DISEASES IMPORTANT TO TENNESSEE. 

Coronaviruses cause the most economically important disease in chickens, 
avian infectious bronchitis, and are a cause of one of the most economically 
important disease syndromes in pigs and calves, neonatal scours. In pigs alone, the 
estimated annual cost in the U. S. due to coronavirus enteritis is 200 million dollars. 
DR. .D. BRIAN'S laboratory, which is entirely devoted to the study of coronaviruses, 
investigates coronaviruses that infect many animal species, including humans, and 
cause disease ranging from severe acute respiratory and gastroenteric disease to 
chronic disease of the central nervous system. Recent evidence suggests that human 
coronavirus is causally related to multiple sclerosis. Dr. Brian's laboratory has recently 
cloned a subgenomic replicon of the bovine coronavirus that is proving useful for 
establishing the mechanisms of coronavirus RNA replication and persistence. The 
replicon may prove useful as an exciting new recombinant vaccine vehicle for 
stimulating mucosal immunity and for delivering medically therapeutic molecules. 
Over the past year, a major research focus in DR. S. OLIVER'S laboratory has 
been on Streptococcus uberis, an important mastitis pathogen that is very difficult to 
control. Results of these studies have shown that both encapsulated and 
unencapsulated strains of 5.. uberis adhere to bovine mammary epithelial cells and to 
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extra cellular matrix proteins such as laminin, fibronectin and collagen. Preliminary 
studies suggest that adherent bacteria become internalized or penetrate a bovine 
mammary epithelial cell line. If internalization occurs in vivo, this could allow S. 
uberis to evade host defenses, and gain access to stromal tissue. Studies are in 
progress to determine if epithelial cell internalization is a potential virulence factor 
in the pathogenesis of S. uberis mastitis. They showed that encapsulated strains of 
S. uberis were more resistant to phagocytosis by mammary gland macrophages than 
unencapsulated strains. Thus, the capsule which surrounds about 50% of S. uberis 
isolates may be a virulence factor by inhibiting phagocytosis. They also evaluated 
the use of new epidemiological markers to studying S. uberis mastitis in dairy cows. 
Results showed that polymerase chain reaction-based DNA fingerprinting and 
bacteriocin-like inhibitory substance (BLIS) fingerprinting as epidemiological markers 
allowed tracing of an infection by the same clonal type in a cow over time. New 
intramammary infections by different clonal types were also identified. Lastly, a 
polymerase chain reaction-based DNA fingerprinting assay was developed as a method 
for identification of Streptococcus and Enterococcus species isolated from bovine milk. 
Several studies were initiated/completed in DR. J. OLIVER'S laboratory during 
the past year. The first project entitled "Lysergic acid amide (lysergamide) 
vasoconstrictor activity in the lateral saphenous vein and dorsal metatarsal artery of 
cattle" encompassed lysergamide induced contraction in these blood vessels which 
has considerable biological implications to the fescue toxicosis syndrome. USDA 
researchers identified this alkaloid in 1991 as being one of the major alkaloids present 
in endophyte-positive fescue grass. The alkaloid was determined to have affinity for 
the serotonergic-2 (5-HT2) receptor, which is present in many organ systems, 
including the brain, kidneys, and gastrointestinal tract in particular. Thus, the 
alkaloid may ultimately be proven to have important biomedical uses in addition to 
contributing to the toxic fescue syndrome. Work has also been completed in 
describing the use of the Alzet™ osmotic pump system for dosing animals with 
purified alkaloids found in toxic tall fescue. The technique will continue to be used 
in studies designed to determine the chronic effects of toxic fescue alkaloids on 
tissues. Further, HPLC methodology has been developed and published to 
determine the content of lysergamide in cattle serum. DR. 1. OLIVER'S group was the 
first to report detecting this important new alkaloid of toxic fescue in the sera of cattle 
grazing endophyte-positive fescue pastures. Finally, efforts continue to secure funds 
from pharmaceutical firms to develop an anti-fescue toxicosis vaccine, for which Dr. 
Oliver has applied for a patent. 
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Goal 6: 	 To IMPROVE THE CAPABILmES OF THE COLLEGE OF VETERINARY MEDICINE, THE 
COLLEGE OF AGRICULTURE, AND THE AGRICULTURAL EXPERIMENT STATION TO DEAL 
WITH THESE DISEASES. 
Work continues on the molecular biology and immune response to bovine 
viral diarrhea virus. DR. L. POTGIETER'S laboratory has as their goal with BVDV 
research, the development of improved diagnostics and immunoprophylaxis. 
Investigation focuses on the structural proteins of this virus. These proteins are 
responsible for induction of the protective immune response. The three major 
structural protein-encoding genes have been cloned, analyzed, and expressed. Using 
these expression products, their goal is to develop a sensitive and specific serological 
test that is very economical. Further, these proteins may be subcloned into live virus 
vectors for use in recombinant live vaccines. Antibodies induced by these proteins 
in animals were found to have neutralizing capabilities. This pathogen is associated 
with respiratory and reproductive disease leading to considerable financial loss. 
Improvement in these two areas of BVDV control, diagnosis and immunoprophylaxis, 
will have significant impact on the cattle industry. 
Additionally, work is ongoing to evaluate the ovine respiratory syncytial virus 
at the molecular level. The surface protein responsible for viral attachment and 
induction of protective immunity to this virus, the G glycoprotein, has been cloned 
and sequenced, and the nucleotide sequence has been extensively analyzed. The 
gene encoding the nonstructural proteins IA, IB, and IC of ORSV has also been 
cloned, sequenced, and analyzed. This is the only ruminant RSV lA-C genes to be 
sequenced to date. Cloning and sequencing of the G glycoprotein of ovine RSV adds 
to the information they have from the bovine RSV. This knowledge will be useful 
for the development of sensitive and specific diagnostic assays, as well as for the 
development of an effective vaccine. Further, the analogy to the human RSV may 
prove to be very useful for development of a suitable animal model for this significant 
human pathogen. This work is of interest to NIH, and we anticipate significant 
extramural funding next year. The sequencing of the 1 C gene will also be important 
for guiding vaccine and diagnostic assay development. 
Goal 7: 	 To IMPROVE FACILITIES TO ENABLE TIlE COLLEGE OF VETERINARY MEDICINE TO SI'UDY 
MORE EFFECTIVE INFECTIOUS AND TOXIC DISEASES AFFECTING ANIMALS. 
The COE research efforts are housed in the Clyde M. York Veterinary 
Medical Teaching Hospital which contains clinical and teaching facilities as well as 
modern research laboratories. Other collaborative research space is located in 
McCord Hall (Animal Science), Walters Life Science Building (Microbiology), and 
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at the University of Tennessee Medical Center and Memorial Research Hospital 
(Medical Biology). 
The center enjoys excellent, but not expansive, research and graduate 
education facilities. The past several of years have been difficult ones from a fiscal 
standpoint, and little funds have been available for the expansion of facilities. We 
regard talented people as more important than facilities, and in the past few years, 
we have had to focus our attention on not losing any important human resources. 
Funds have recently been made available for the planning phase of a new 
Biotechnology Building on the Institute of Agriculture Campus. If USDA and State 
of Tennessee matching funds can be secured, such a building would provide at least 
some additional research space for COE researchers and graduate students. 
Goal 8: To DISSEMINATE THROUGH THE EXTENSION SERVICE THE PRAcrICAL INFORMATION 

REQUIRED TO REDUCE THE INCIDENT OF LIVESTOCK DISEASES. 

UTCVM has been featured in several publications over the course of the 
year. UT Agriculture, published by the Institute of Agriculture and encompassing a 
large statewide audience, featured an article on DR. T. SCHULTZ pertaining to 
toxicological issues as they relate to birth defects. Veterinary Medical Topics, 
published semi-annually by the Extension Service, routinely features articles 
exploring livestock diseases. Channel 10 featured the genetic mouse model that is 
part of DR. E. WILKINSON'S research. This same feature was later picked up and 
shown nationally on CNBC. Regular features appear as well in the two UT alumni 
publications, Context and the Torchbearer. 
Goal 9: To DEVELOP NEW STRATEGIES FOR THE PREVENTION OF DISEASE. 
During the past year, COE has supported DR. K. HAHN'S two Cytogenetics 
Laboratory pilot investigations in genetic toxicology. Project 1 entitled 
"Quantification of in vitro induced sublethal DNA damage by photodynamic 
therapy," determined if chloroaluminum-sulfonated phthalocyanine (AISPc) 
photodynamic therapy (PDT) caused sublethal DNA damage in EMT-6 mouse 
sarcoma cells treated in vitro. The second project titled "Micronuclei assay: A 
predictive indicator for tumor response to treatment" determined if anti-neoplastic 
drugs such as cyclophosphamide, doxorubicin HCI, and cis-diammine-dichloro­
platinurnII induced sublethal DNA damage in normal circulating canine peripheral 
blood lymphocytes cultured in vitro and if the degree of damage was of predictive 
value for in vivo treatment response in tumor-bearing dogs. The endpoint of study 
for both projects was evaluating the formation of cellular micronuclei. Micronuclei are 
fragments of DNA packaged independently during cellular division and are 
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quantitatively significant as an indicator of sublethal DNA damage. With this prelinary 
data, Dr. Hahn plans to submit a first investigator's grant to NIH. 
DR. T. ROWLES has begun developing protocols for in vitro testing and kinetics 
of neurotoxicants. Cytotoxicity assays in endothelial, glial, and neuronal cells were 
established. Toxicant testing is planned for next year. Additionally, an in vitro 
model of the blood-brain barrier will be developed by co-culturing these cell types. 
Goal 10: To IMPROVE FACILITIES AND EXPERTISE IN ORDER TO PROVIDE IMPROVED RESEARCH 

TRAINING. 

SPECIAL MATERIALS AND EQUIPMEI\'T 
Equipment monies this year were spent on assisting with the establishment of 
laboratories of three new Center members--DRS. K. HAHN, C. MENDIS-HANDAGAMA, and 
T. ROWLES. This mainly encompassed upgrade tissue culture and molecular biology 
capabilities. As well, several multiuser pieces of equipment were purchased, 
including three centrifuges, a gas chromotograph, and a tumor analysis system. 
GRADUATE STUDENTS. POST DOCTORAL RESEARCHERS. AND RESIDENTS 
Dr. David Dean, sponsored by DR. D. SLAUSON, was the first student in the 
college to receive an individual NIH research training grant. He is studying the 
"Signalling pathways in LPS-stimulated lung macrophages." 
Dr. Donna Bouley became the second student in the college to receive an 
individual NIH research training grant. Under the direction of her advisor, DR. B. 
ROUSE, Dr. Bouley will study "Herpetic stromal keratitis pathogenesis: An animal 
model." 
These NRSA Fellowship Awards are very competitive at a national level, so 
it is very gratifying that these proposals have been selected for funding. COE 
monies are used to support the research of our NRSA fellows. 
Our training program is small, but high in quality. An institutional training 
grant has been submitted by DR. D. SLAUSON, Department of Pathobiology. If 
funded, it will support five graduate students/residents selected from the 
Comparative and Experimental Medicine Graduate Program. These students will 
train in the area of "Cellular Pathobiology of Environmental Disease." The program 
will be a collaborative effort between the Department of Pathobiology and the 
Biology Division at Oak Ridge National Laboratory. The program will seek to 
produce individuals who, by virtue of their training, will be uniquely equipped to address 
such important environmental research priorities as the molecular and genetic basis for 
disease, genetic and membrane events that may control differentiation and 
development, the role of receptor-mediated pathobiology including transmembrane 
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signal transduction, molecular mechanisms of chemical carcinogenesis, and the 
molecular and genetic basis for immunologic susceptibility and predisposition. The 
graduates of this program should then be able to contribute to an enhanced 
understanding of the environmentally-caused disorders of man and other animals 
both in terms of the morphologic expressions of disease and in terms of its 
molecular and cellular pathogenesis. 
Several young research associates and residents have benefited directly from 
the use of COE funding to provide for preliminary data via venture grants. A few 
examples include Dr. Huda AI-Ansari, a post doctoral research associate, with DR. 
L. POTGIETER who received funding from USDA for their project entitled 
"Significance of strain variation within the ruminant respiratory syncytial viruses." 
This funding will enable them to determine the seroprevalence of the prototype 
ORSV in cattle, to determine variability among BRSV isolates using RNase A 
mismatch analysis, and to establish the number of RSV subgroups infecting cattle. 
These goals could provide important data that would help determine which RSV strains 
should be incorporated into a multivalent vaccine to effectively control the disease in 
cattle. 
Dr. Wendy Davies-Dean has received a grant from the American Animal 
Hospital Association (AAHA) for $6,100 for her study entitled "Evaluation of 
intraosseous administration of total parenteral nutrition in cats." Nutritional 
support of injured or ill dogs and cats is recognized as a vital component of case 
management. Her goal is to provide an option for practitioners in cases where 
parenteral nutritional support is necessary but delivery by traditional routes has failed or 
is impossible. Hopefully by making parenteral nutrition more accessible, this 
potentially lifesaving therapy will be used more routinely. 
MINORITY RECRUITMENT 
To compliment the Minority High School Apprentice Program sponsored by 
the National Institutes of Health (now in its 12th year), a new veterinary internship 
for African-American High School Students in Tennessee has been developed with 
funding provided by a grant from the Tennessee Higher Education Commission. 
While the students participating in the NIH sponsored program spend 8 weeks at 
the college, the veterinary internship program participants sponsored by THEC, will 
be working with a veterinarian in their home towns for eight weeks during which 
one week they will be introduced to the UTCVM and UT campus. 
Through our minority internship/residency program, UTCVM has been 
successful in recruiting 5 minorities for the upcoming fiscal year. 
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COLLABORATIVE RESEARCH PROJECTS 
To further determine if absence of PDGF-Q receptors interferes with 
placental growth, DR. L. MUNSON is now collaborating with the University of 
Washington-Seattle to evaluate a spontaneous PDGF-Q receptor-deficient mouse 
model, the Patch mouse. To evaluate placental development in the Patch mouse, 
they have developed riboprobes and initiated in situ hybridization techniques in 
their laboratory. These new molecular techniques will be used to identify 
homozygous PDGF-QR mutant embryos so that the development of their placenta 
can be evaluated. 
In collaboration with Dr. Ellis Avner of the University of Washington, 
Seattle, DR. E. WILKINSON has begun to characterize the kidney cells involved in the 
production of the lesions in the Tg737 mice. Their preliminary data suggests that 
the cells are principal cells and that the lesion develops as a result of a failure of 
maturation of the principal cells and the differentiation into the specialized intercalated 
cells. Similarly, the liver lesion appears to arise from a failure of differentiation of 
the liver stem cells into mature biliary epithelium. 
In other studies, they have cloned and sequenced the human homolog of the 
mouse Tg737 gene and established the molecular structure of the intron-exon 
boundaries. In collaboration with Dr. Steve Reeders of Howard Hughes Medical 
Institute, Yale University, they are examining the structure of the Tg737 gene in over 
100 human families with autosomal recessive polycystic kidney disease. Further, Dr. 
Wilkinson has also completed collaborative studies with Dr. Greg Dressler of the 
National Institutes of Health (NIH) on the nature of the congenital nephrotic 
syndrome in PAX-2 transgenic mice. 
As well, Dr. Wilkinson's laboratory has established cultures of liver and kidney 
cells from Tg737 mice. Several lines of liver cells have been developed and from 
mice with different genetic backgrounds. A Cooperative Research and 
Development Award has been established through the Oak Ridge National 
Laboratory and Proctor & Gamble to further characterize the putative liver stem 
cells. 
Collaborative work was initiated between DR. J. OLIVER and researchers at 
the University of Arkansas to characterize the activity of a purified ergovaline 
preparation developed by them using Dr. Oliver's isolated bovine blood vessel model. 
Further, collaborative work has also been initiated between Dr. Oliver with other 
UTCVM researchers and Clemson University, to characterize in utero biochemical 
changes in placental fluids in mares on endophyte-infested and endophyte-free tall 
fescue pastures. Two graduate students, one resident and five faculty members 
between the two institutions are involved in the project. 
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Goal 11: To DEVEWP INNOVATIVE APPROACHES TO THE TREATMENT OF HUMAN DISEASE. 
One aspect of DR. B. ROUSE'S work involves designing delivery vehicles that 
optimize induction of cytotoxic T lymphocytes with viral proteins and peptides. This 
program, which proceeds collaboration with Dr. Leaf Huang, University of 
Pittsburgh, uses liposomes as carriers of autogens and adjuvants. This approach to 
vaccinate may prove valuable to prevent certain human virus infections. 
The effects of sex- and strain-related differences in megakaryocytopoiesis 
and platelet production in C3H and BALB/C mice were studied during the year by 
DR. T. McDoNALD. The studies were carried out on castrated male and 
ovariectomized female C3H and BALB/C mice, along with suitable intact controls. 
The results support their previous work, showing that intact male BALB/C mice 
had higher platelet counts and %35 S incorporation into platelets than did intact 
female BALB/C mice. Further, both intact BALB/C and C3H male mice had 
higher platelet counts than their castrated counterparts. Castration caused 
increased numbers and decreased sizes of megakaryocytes in both strains of mice. 
Although a difference in megakaryocyte ploidy was not detected between intact 
male and intact female C3H mice, BALB/C female mice had lower ploidy 
megakaryocytes than did BALB/C male mice. Castrated BALB/C mice had lower 
ploidy megakaryocytes than did intact BALB/C male mice. They found a shift to a 
lower ploidy class with the removal of gonads in male mice; therefore, they believe 
that this finding is consistent with the hypothesis that male sex hormones cause an 
increase in polyploidy and size of megakaryocytes. In order to understand 
thrombocytopoiesis during pregnancy, megakaryocytes and platelets were examined 
during gestation and the early postpartum period, using the rat as a model. Mean 
platelet volume and platelet volume distributions were not significantly altered in 
late gestation of rats. Also, they showed that platelet survival in pregnant rats was 
not significantly different from that of non-pregnant females. In contrast, 
megakaryocyte concentration was significantly increased during late gestation and 
early postpartum. Their data indicate that thrombocytopoiesis is substantially 
increased during late pregnancy, and that this increase is accompanied through an 
increase in megakaryocyte DNA content and size, as well as, megakaryocyte number. 
The data also revealed that pregnancy-associated hormonal changes which produce an 
increase in megakaryocyte DNA content and size differ from those which cause an 
increase in megakaryocyte number. 
During the past year, COE provided support for a post-doctoral fellow to 
work with DRS. D. FRAZIER and DR. M. BREIDER. The project entitled "Enhancement 
of photodynamic tumor therapy with angiogenic cytokines" was supported by the 
Thompson Cancer Survival Center. This project examined the effect of cytokines on 
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cytOXIClty induced by photsensitizing drugs in tumor cells and endothelial cells. 
Preliminary drug transport studies were conducted. The proposal to the Beckman 
Laser Institute will examine transport of these photosensitizing agents across the blood­
brian barrier and cytotoxicity to neuroblastoma cells, brian capillary endothelial cells 
and astrocytes. COE has also provided support for two doctoral students. The two 
projects (1) use of photodynamic therapy for autologous bone marrow 
transplantation and (2) synergistic activity of cisplatin and radiation, will be 
completed this year. 
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II. BENCHMARKS 
Table 1. CENTER OF EXCELLENCE IN LIVESTOCK DISEASES AND HUMAN HEALTH 
BENCHMARKS OF FACULTY ACCOMPLISHMENTS 
FACULTY MEMBERS ASSOCIATED 
WITH THE CENTER OF EXCELLENCE 
A. Numbers of 
Year 5 
(Final Year of 
Initial Commitment) 
1988-89 
Target Actual Avg 
Year 6 
(Year 01 as 
Accomplished Center) 
1989-90 
Actual Avg 
Year 7 
(Year 02 as 
Accomplished Center) 
1990-91 
Actual Avg 
YearS 
(Year 03 as 
Accomplished Center) 
1991-92 
Actual Avg 
Year 9 
(Year 04 as 
Accomplished Center) 
1992-93 
Actual Avg 
1. Articles 
2. Books or book chapters published 
3. Published proceedings 
74 
7 
21 
(3.22) 
(0.30) 
(0.91) 
68 
17 
37 
(2 .62) 
(0.65) 
(1.42) 
97 
14 
42 
(3.73) 
(0.54) 
(1.62) 
83 
6 
24 
(4.37) 
(0.32) 
(1 .26) 
78 
7 
17 
(3.90) 
(0.35) 
(0.85) 
b::I 
~ 
;:::s 
("')
;:s­
~ 
~ ~ 
Total Publications: 2.82 102 (4.43) 122 (4.69) 153 (5.89) 113 (5.95) 102 (5.10) 
B. *Number of invited participations at: 
1. Regional Meetings 0.50 36 (1 .56) 19 (0.73) 28 (1 .08) 13 (0.68) 15 (0.75) 
2. National Meetings 1.25 55 (2.39) 28 (1 .08) 44 (1 .69) 36 (1 .89) 47 (2.35) 
C. Abstracts 0.30 33 (1 .43) 66 (2 .54) 48 (1 .85) 47 (2.47) 53 (2.65) 
Number of faculty included in Center 23 26 26 19 20 
Number of Visitors 11 10 17 17 12 12 
~ 
I-l 
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TABLE 2. 
RESEARCH PROJECTS FUNDED EXTERNALLY 
PROJECT DIRECTOR 
BOCHSLER, P. N. 
Bovine Lipoplysaccharide Binding 
Protein and Mechanisms of 
Macrophage Activation 
BOCHSLER, P. N. 
Molecular Basis of 
Endothelial Cell Sensitivity to 
Lipopolysaccharide 
BOCHSLER, P. N. 
The Bovine CD 14 Receptor: 
A Link in Endotoxin-mediated 
Macrophage Activation 
BRIAN, D. A. 
Corona virus Structure and 
Replication 
BRIAN, D. A. 
Mechanism(s) of Corona virus 
RNA Replication and Packaging 
DAWSON, D. A. 
SCHULTZ, T. W., Co-investigator 
Mixture Teratogenesis: Relation 
to Mechanisms and QSARs 
HAHN, K. 
SCHULLER, H. M., Co-investigator 
Contract--B859-035 Treatment 
of Dogs with Osteosarcoma 
McDoNALD, T. P. 
Contract--Development ofAssays 
for Thrombopoietin 
Performance ofAssays for 
Thrombopoietin 
McDoNALD, T. P. 
Characterization of 
Thrombopoietin 
McDONALD, T. P. 
Thrombopoietin: Immuno­
assay & Characterization 
REPORT PERIOD 1992-93 
SOURCE 
USDA 
9/1/91-8/31/93 
(Extension to 8/31 /94) 
USDA 
9/15/92-9/30/94 
USDA 
9/15/92-9/30/94 
NIH 
9/1/89-8/31/94 
USDA 
9/15/92-9/30/95 
NIEHS/NIH 
4/1/91-3/31/93 
BYK Gulden 
Pharmaceuticals 
1/1/93-12/31/95 
Genentech 
3/1/88-2/28/93 
(Extension to 2/28/95) 
3/1/88-7/31/93 
(Extension to 2/28/95) 
AmGen 
10/1/92-12/31/95 
NIH 
12/1/88-11/30/93 
TOTAL AMOUNT ESTIMATED 
AWARDED EXPENDITURES 
7-1-92/6-30-93 
140,000 42,000 
95,000 37,601 
150,000 59,375 
552,187 140,716 
200,000 52,782 
138,043 51,768 
63,890 21,120 
175,832 29,304 
112,700 18,780 
73,671 17,001 
548,681 109,740 
PROJECT DIRECTOR 
McDONALD, T. P. 
Purchase of: Matrix 96 Direct 
Beta Counter 
MUNSON, L. 
The Pathological Effects of 
Melengestrol Acetate in Captive 
Wild Felids 
OLIVER, S. P. 
Mastitis Research 
OLIVER, S. P. 
Mastitis Research 
OLIVER, S. P. 
Factors Influencing Bovine 
Mononuclear Cell Function during 
the Nonlactating Period 
OLIVER, S. P. 
Mastitis Research 
Effectiveness of 
chlorhexidine as a premilking 
teat disinfectant for the 
prevention of bovine mastitis 
Chlorhexidine Milk Residues 
Associated with Premilking 
and Postmilking Teat 
Disinfection 
OLIVER, S. P. 
Mastitis Research 
Immunization of dairy cows 
against Streptococcus uberis: 
Efficacy of an Experimental 
Vaccine during the Nonlactating 
Period 
OLIVER, S. P. 
Selenium and Vitamin E in 
Disease Resistance 
OLIVER, S. P. 
Use of Genetic Markers as 
Indicators of Mastitis 
Resistance and Milk Production 
in Jersey Cattle 
Benchmarks 
SOURCE 
NHLBI Small 
Instrumentation Program 
9/1/92-8/31/93 
AAZPA 
Conservation Center 
10/1/92-9/30/93 
Alcide Corporation 
12/90-12/94 
Monsanto Agri Co 
11/90-12/92 
USDA-SEA 
9/ 90-9/ 92 
H. B. Fuller Co. 
4/ 91 -12/94 
H. B. Fuller Co. 
1992-1993 
H. B. Fuller Co. 
1992-1993 
Upjohn Company 
10/91 -12/94 
Upjohn Company 
1991-1993 
BASF 
1992-1993 
American Jersey 
Cattle Club 
1993 
18 
TOTAL AMOUNT ESTIMATED 
AWARDED EXPENDITURES 
7-1-92/6-30-93 
17,225 17,225 
37,807 28,359 
57,752 14,438 
25,576 12,788 
98,388 12,300 
31 ,778 8,664 
24,052 12,026 
3,732 3,732 
6,293 1,992 
54,225 27,112 
17,000 10,000 
6,000 3,000 
PROJECT DIRECTOR 
POTGIETER, L. 
Development of Technology for 
use in the Discovery and 
Production of a Commercial BVD 
Vaccine and Diagnostic 
POTGIETER, L. 
Cloning and Sequencing of BRSV 
G Glycoprotein and Detection 
of Strain Divergence 
ROUSE, B. T. 
Immunity Mechanisms in 
Herpesvirus Infections 
ROUSE, B. T. 
Keratitis Treatment with Drug-
containing Immunoliposomes 
Mechanisms in Herpetic 
Stromal Keratitis 
ROUSE, B. T. 
Liposome Microencapsulation 
of Vaccine Antigens 
ROUSE, B. T. 
Herpes Zosterification 
ROWLEST. K. 
Characterization Isolated 
Rodent Microvesse/sj 
Astrocytes Co-cultures 
SCHULLER, H. M. 
Mechanisms of Neuroendocrine 
Lung Carcinogenesis by 
Nitrosamines 
SCHULLER, H. M. 
Transplacental 
Carcinogenicity of NNK 
SCHULLER, H. M. 
Characterization of Induced 
Neuroendocrine Lung Cancer 
SCHULLER, H. M. 
Contract--Testing ofAnti-
carcinogenic Effects of 
Niguldipine 
Benchmarks 
SOURCE 
Upjohn Company 
2/1/90-12/31/92 
USDA Special 
Grant 
8/1/90-7/31/93 
NIH 
5/1/89-4/30/94 
National Eye 
Institute (NIH) 
9/30/87-9/29/92 
National Eye 
Institute (NIH) 
9/30/92-9/29/97 
NIAID 
6/1/90-5/31/95 
Smithkline Biologicals 
12/15/89-12/31/94 
Environmental Protection 
Agency (EPA) 
4/7/93-4/6/95 
Shannon Award 
Institute (NIH) 
9/1/91-8/31/93 
NIH 
9/1/89-11/30/92 
(Extension to 11/30/93) 
National Cancer 
Institute (NIH) 
2/7/92-1/31/95 
Byk Gulden 
Pharmaceuticals 
3/1/88-12/31/94 
19 
TOTAL AMOUNT ESTIMATED 
AWARDED EXPENDITURES 
7-1-92/6-30-93 
75,000 25,000 
149,974 49,991 
1,130,370 234,132 
718,935 38,907 
774,745 152,586 
828,289 162,807 
124,746 25,000 
9,484 789 
100,000 48,504 
491,219 93,137 
464,975 176,642 
382,925 52,497 
PROJECT DIRECTOR 
SCHULTZ, T. W. 
Chaos in Microbial Systems 
SHULL, R. 
Molecular Study of MPS I: 

Gene Therapy in a Canine Model 

SLAUSON, D. O. 
Leukocyte Function and Host 
Defense in Developing Calves 
SLAUSON, D., Advisor for 
D.Dean 
Signalling Pathways in LPS-
Stimulated Lung Macrophages 
WILKINSON, J. E. & 
GODKIN, J., Co-investigator 
Transforming Growth Factors in 
Early Pregnancy in the Cow 
WILKINSON, J. E. 
Molecular Genetics of PKD in 
the Transgenic TG737 Mouse 
WILKINSON, J. E. 
Immunobiology of the Scurfy 
Mouse 
Total 
Benchmarks 
SOURCE 
NSF 
12/1/89-11/30/92 
NIH 
8/1/92-7/31/96 
USDA Competitive 
8/15/90-9/30/93 
(Extension to 9/30/93) 
NIH Training Grant 
11/30/ 91 -11/30/94 
USDA Special 
8/1/89-6/30/92 
(Extension to 6/30/93) 
NIH 
9/30/ 92-9/29/95 
NIH 
9/ 30/ 92-5/31/95 
20 
TOTAL AMOUNT ESTIMATED 
AWARDED EXPENDITURES 
7-1-92/6-30-93 
111 ,615 15,500 
1,001,653 114,944 
120,000 39,000 
97,500 26,540 
149,653 35,488 
406,639 121 ,608 
579,594 143.464 
$2,288,359 
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III. PLANS FOR NEXT YEAR 
CARCINOGENESIS AND DEVELOPMENTAL THERAPEUTICS GROUP 
DR. H. SCHULLER will continue to pursue research goals and devote considerable 
efforts to the integration of other faculty into the interdisciplinary research programs under 
the umbrella of the "Carcinogenesis and Developmental Therapeutics Program. Dr. 
Schuller has served on four NIH site visit teams for the review of Cancer Center grants and 
program project grants, and she was an ad hoc member of two NIH study sections. She has 
agreed to become a regular member of the NIH chemical pathology study section in 
January 1994. Dr. Schuller has also been appointed as associate editor of the international 
journal Carcinogenesis. 
Fetal tissues are more sensitive to the effects of chemical and physical carcinogens 
than are adult tissues. This suggests that the embryos and fetuses of pregnant women are 
at a greater risk of developing cancer from environmental exposures than is the adult 
population. It is thus important to gain further understanding of the mechanism(s) that 
help modulate the fetal organism's response to environmental toxicants, and to determine 
how the genetic background of the individual fetus and its mother can modulate its 
response to envrionmental carcinogens. DR. M. MILLER'S goal for the coming year is to 
determine the molecular mechanisms governing the pathogenesis of lung tumors in mice 
differing in their susceptibility to polycylic hydrocarbon-mediated tumor formation. The 
data will show how the genetic make-up of the individual and the modulating influences of 
maternal phenotype can influence susceptibility to cancer as a result of early in utero 
exposure to environmental chemicals. 
DR. K. HAHN'S long term goal for the Cytogenetics Laboratory is to determine the in 
vitro and/or in vivo efficacy of novel cancer treatment strategies using proven methods in 
genetic toxicology. With recent support from Bristol Laboratories and the National Cancer 
Institute of donated drugs, he will seek to determine quantitatively if SR-2508 
(etanidazole), an oxygen-mimetic nitroimidazole, potentiates sublethal DNA damage and 
cytotoxicity in EMT-6 tumor cells and/or normal peripheral blood lymphocytes when 
concurrently exposed to subtherapeutic doses of either radiation or chemotherapy in vitro. 
GROWTH FACTORS GROUP 
DR. R. SHULL will continue to investigate methods of either stem cell enrichment or 
elimination of differentiated cells from populations to be subjected to gene transfer. Even 
with relatively high titer vectors, working with unenriched marrow mononuclear cells 
requires very large volumes to be effective. Monoclonal antibodies to c-kit, the target for 
stem cell factor have been obtained, and they will test these by F ACS in the coming year. 
Another antibody (DH59B) reacts with an epitope on differentiated granulocytes and 
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For DR. T. ROWLES, next year will involve further development of protocols for the in 
vitro assessment of neurotoxicity. These protocols include transport studies, transepithelial 
electrical resistance and biochemical assays. Such protocols will be used to assess the 
integrity of an in vitro model of the blood brain barrier. A valid model of the blood brain 
barrier will allow drug and toxicant testing with a reduction in the number of animals used and 
an increase in the numbers of chemicals tested. Additionally, this model will provide a way 
to study mechanisms of neurotoxicity. 
DR. D. FRAZIER is working with DRS. T. ROWLES and T. SCHULTZ to develop an in vitro 
model of the blood-brain barrier for evaluation of transport and cytotoxicity of 
environmental toxicants and cancer chemotherapeutics. Preliminary studies of Dr. Frazier 
and others suggested that cytokines are important mediators of transport of cytotoxic drug!! 
across peripheral capillary endothelial cells and into tumor cells. Angiogenic cytokines 
may be even more important as mediators of transport across brain capillary endothelial 
cells (blood-brain barrier). 
INFECTIOUS DISEASES AND POPULA nON MEDICINE GROUP 
DR. D. BRIAN'S research is a systematic analysis of the molecular structure, 
replicational strategy, and medical significance of coronaviruses, one family of RNA viruses 
that cause primarily gastroenteric and respiratory diseases in animals and humans. Their 
major effort focuses on two gastroenteric coronaviruses, the porcine, transmissible, 
gastroenteritis, coronavirus (TGEV) and the bovine enteric coronavirus (BCV). Both are 
significant veterinary pathogens and each serves as a model for one of two major antigenic 
subgroups of mammalian centeric coronaviruses. They also conduct some studies on the 
mouse hepatitis coronavirus and human coronaviruses. 
Additional structural and nonstructural protein-encoding genes of ORSV have been 
cloned in DR. L. POTGIETER'S laboratory. In the next year, these ORSV recombinant clones 
will be sequenced and analyzed, as has been done for the G and 1 C genes. They also plan 
to subclone the ORSV genes into the baculovirus expression system for production and 
analysis of ORSV proteins. Eventually, they hope to evaluate the immune response to, and 
correlates of protection for ruminant RSV. Furthermore, since it is not known if ovine 
RSV strain is circulating in cattle, his laboratory plans to assess the presence of antibodies 
to their ovine RSV G glycoprotein serum samples from cattle in different geographical 
locations using a sensitive immunoassay such as ELISA. Such information is important to 
determine strain variability among cattle and to identify the strain necessary for inclusion 
in any multivalent vaccine. They also plan to continue investigation of the protective 
nature of the structural proteins of BVDV individually and in combination with one 
another, as well as continue efforts to develop economical and accurate diagnostic assays. 
DR. J. OLIVER will participate in endophyte-free and endophyte-positive tall fescue 
pasture studies. Studies will include collection of both forage from pastures and serum 
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from cattle throughout the grazing season to determine alkaloid content by HPLC and GC 
methods. These profiles will be correlated with other physiological response factors, 
including animal growth, hair quality scores, serum prolactin, serum endothelin and serum 
cortisol levels. 
DR. S. OLIVER will be working on a new project entitled "DNA probes for typing and 
sub typing bacterial pathogens isolated from dairy cattle." Application of DNA probes for 
identification and sUbtyping of pathogenic bacteria could allow diagnostic laboratories to 
examine a wider variety of organisms, enable identification of bacterial pathogens that 
cannot be cultured easily in vitro, allow rapid screening and subtyping of a large number of 
organisms which would be very useful during an outbreak of an animal disease, enhance 
development of strategies for monitoring disease control programs and reduce costs of 
handling, processing, identification and subtyping of bacterial pathogens. The objective for 
the first year of this study is to develop a model system for identification of pathogenic 
bacteria using specific oligonucleotide primers targeted at 16 S rRNA sequences. 
INFLAMMATION AND HOST DEFENSE GROUP 
During the next academic year DR. B. ROUSE'S efforts will be directed at finding 
explanations for the preferential accumulation of CD4 + T cells in ocular tissues identifying 
possible target antigens which they recognize and evaluating the role of nitric oxide radicals 
as responsible for tissue damage. 
DR. P. BOCHSLER will expect to explore new research possibilities as they arise by 
incorporating new techniques, and by pursuing collaborative studies when bovine LBP is 
isolated and purified in sufficient quantity. Should opportunity arise, to continue PMN­
related research, he would like to continue this as time and personnel allow. A specific 
goal is to have at least three research manuscripts published in refereed journals. 
The specific goals for DR. D. SLAUSON for the coming year are to continue to dissect 
the signalling pathways used by LPS and LPS /LBP complexes for pro coagulant induction 
and TNF-a release in bovine lung macrophages with special attention directed at the 
potential role of a G-protein linked receptor in the proximal pathway and a C-kinase as a 
terminal activator. The data his laboratory has been able to obtain to date support their 
contention that the pathways used by LPS are at least partially G-protein-linked and PKC­
dependent. A second objective will be to determine the role of Ca2+ in these signalling 
pathways. 
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REPORT F 
SCHEDULE 1 

TENNESSEE HIGHER EDUCATION COMMISSION 

CENTERS OF EXCELLENCE 

1992-93 BUDGET AND PROPOSED 1993-94 BUDGET 

1992-93 Actual EX[1enditures 1993-94 Pro[1osed Budge! 
Matching Am~ro[1riations Total Matching A[1[1ro[1riations Total 
Revenue ,­
New State Appropriation 
Carryover from Previous Appropriation 
New Matching Funds 
Carryover from Previous Matching 
253,250 
506,500 506,500 
253,250 253,000 
7,579 
506,000 
15,068 
506,000 
15,068* 
253,000 
7,579 
Total 253,250 506,500 759,750 260,579 521,068 781,647 
Expenditures 
Salaries 
a. Faculty 
b. Other Professional 
c. Clerical/Supporting 
d. Assistantships 
e. Studentlfotal Salaries 
Fringe Benefits 
Total Personnel 
39,250 
54,020 
18,240 
5,070 
Z;566 
124,146 
23,045 
147,191 
78,620 
108,203 
36,539 
10.,155 
' 15,149 
248,666
46,158 
294,824 
117,870 
162,223 
54,779 
15,225 
22,115 
372,812
69,203 
442,015 
40,932 
51,904 
17,773 
8,762 
8,325 
127,696
26,867 
154,563 
81,988 
103,963 
35,600 
17,550 
17,6Z5 
255,776
53,816 
309,591 
122,920 
155,867 
53,373 
26,312 
25,000 
383,472
80,683 
464,1,55 
Travel 416 835 1,.251 1,665 3,335 5,000 
Software 
Books and Journals 
Other Supplies 
Equipment 
~~t~~~'l,rCfeesc 0 ars IpS 
33,874 
58,277 
4,525 
1,389 
67,851 
116,075 
9,063 
2,783 
101,725 
174,262 
13,588
4,172 
· 47,974 
49,950 
4,995
1,433 
95,219 
100,050 
10,005
2,868 
143,i92 
150,000 
15,000
4,300 
Consultants 
Renovation 
Other (Specify) 
Total Non-personnel 98,481 195,607 294,998 106,016 211,477 317,492 
GRAND TOTAL 245,6Z1 491 ,432 737,013 260,579 521,068 78~,647 
*There was $6790 obligated in equipment that did not get paid in 92-93. 
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NAME: Kevin A. Hahn 
TITLE: Assistant Professor 
APPOINTMENT: Dept. of Environmental Practice 
EDUCATIONAL BACKGROUND: 

Degree Year University Major 
PhD 1992 Purdue Cytogenetics/Oncology 
DVM 1987 Purdue Veterinary Medicine 
BS 1983 Purdue Animal Sciences 
CAREER HISTORY: 
Year(s) Title Employer 
1991 - present Assistant Professor of Oncology Univ. of Tennessee 
1987 - 1992 Cytogenetics Research Fellow Purdue University 
1988 - 1991 Clinical Oncology Resident Purdue University 
1987 - 1988 Clinical Oncology Intern Purdue University 
PROFESSIONAL SOCIETIES: 
American Veterinary Medical Association, Veterinary Cancer Society, Veterinary Cooperative 
Oncology Group, American Association for Cancer Research, Association of Cytogenetic 
Technologists, International Society for the Study of Comparative Oncology, American Cancer 
Society, Knox County Unit. 
SCIENTIFIC PUBLICATIONS 

- Abstracts. Proceedings, & Non-peer reviewed, (total - 41). 1992 - July 1. 1993: 

Hahn KA, Morrison WB, Chan TC. The concentration of doxorubicin and its associated 
metabolites in canine urine following a single administered dose. Tenth Annual Forum, American 
College of Veterinary Internal Medicine, San Diego, CA. May 28-31, 1992. 
Hahn KA, Vonderhaar MA, Teclaw RF. An epidemiological evaluation of 1202 dogs with 
testicular neoplasia. Tenth Annual Forum, American College of Veterinary Internal Medicine, San 
Diego, CA. May 28-31, 1992. 
Hahn KA, Richardson RC. The diagnostic and prognostic importance of cytogenetic aberrations 
identified in spontaneously occurring canine malignant lymphoma. Twelfth Annual Conference, 
Veterinary Cancer Society, Monterey, CA. October 18-21, 1992. 
Bravo L, Hahn KA, Legendre AM, Daniel GB, Frazier DL, Rohrbach BW. Evaluation of pre­
and post-cisplatin renal function in 23 tumor-bearing dogs. Twelfth Annual Conference, Veterinary 
Cancer Society, Monterey, CA. October 18- 21, 1992. 
Arrington KA, Frazier DL, Tabeling GS, Hahn KA, Legendre AM. The comparison of 
pharmacokinetics, hematologic parameters, and clinical signs of doxorubicin administration in small 
and large dogs. Twelfth Annual Conference, Veterinary Cancer Society, Monterey, CA. October 
18-21, 1992. 
Hahn KA, Richardson RC. The cytogenetic evaluation of 61 dogs with non-Hodgkin's lymphoma 
(NHL). Eighty-fourth Annual Meeting, American Association for Cancer Research, Orlando, FL. 
May 19-22, 1993. 
Hahn KA. Prognostic Tumor Markers. Eleventh Annual Forum, American College of Veterinary 
Internal Medicine, Washingtion, DC. May 20-23, 1993. 
- Referreed Journals (total - 17). 1992 - July 1. 1993: 
Hahn KA, Richardson RC, MA Cline, Teclaw RF, Carlton WW, DeNicola DB, and PL Bonney. 
Is Maintenance Chemotherapy Appropriate for the Management of Canine Malignant Lymphoma? J 
Vet Int Med 1992;6:3-10. 
Hahn KA, Widmer WR. What is Your Diagnosis. J Amer Vet Med Assoc 1992;200:221-222. 
Hahn KA, Knapp DW, Richardson RC, Matlock C. The Clinical Response of Nasal 
Adenocarcinoma to Cisplatin Chemotherapy in 11 Dogs. J Amer Vet Med Assoc 1992;200:355-357. 
Hahn KA, Richardson RC, Knapp DW. Canine Malignant Mammary Neoplasia: Biological 
Behavior, Diagnosis, and Treatment Alternatives. J Amer Anim Hosp Assoc 1992;28:251-256. 
Peter AT, Scheidt AB, Campbell JW, Hahn KA. Male pseudohermaphroditism of the testicular 
feminization type in a heifer. Canadian Vet. Journal 1993; in press. 
Hahn KA, Chan TCK, Morrison WB, Hahn EA. High performance liquid chromatographic 
analysis of doxorubicin and its metabolites in canine urine. J Amer Anim Hosp Assoc, 1993; in 
press. 
Hahn KA, Richardson RC, Hahn EA. Identification and quantification of serum a1pha­
fetoprotein in 50 dogs with spontaneously occurring tumors. Res Vet Sci, 1993; submitted. 
Hahn KA, Richardson RC, Hahn EA, Chrisman CL. The diagnostic and prognostic importance 
of cytogenetic aberrations identified in spontaneously occurring canine malignant lymphoma. Vet 
Path 1993; submitted. 
Bravo L, Hahn KA, Legendre AM, Daniel GB, Frazier DL, Rohrbach BW. Evaluation of renal 
function in 23 tumor bearing dogs treated with cisplatin. J Vet Int Med 1993; submitted. 
Hahn KA, DeNicola DB, Richardson RC, Hahn EA. Canine oral malignant melanoma: The 
prognostic utility of an alternative staging scheme and a review of 41 cases. J Small Anim Pract 
1993; submitted. 
RESEARCH - (Accepted proposals - 22; support - $281 .133). 1992 - July 1. 1993: 
Hahn KA, Frazier DL, Breider MA, Panjehpour M. Quantification of Photodynamic and 
Hyperthermic Induced In vivo Sub-lethal DNA damage. Submitted to Center of Excellence, College 
of Veterinary Medicine, University of Tennessee. Accepted July 1, 1992, $15,000. 
Hahn KA. Micronuclei Assay: A Predictive Indicator for Tumor Response to Treatment. 
Submitted to University of Tennessee College of Veterinary Medicine, Venture Grant Program. 
Accepted July 1, 1992, $3,762. 
Bravo L, Legendre AM, Hahn KA, Lothrop CD. Serum cytokine concentrations in normal dogs 
and in dogs with lymphoma before and after chemotherapy. Venture Grant Program, University of 
Tennessee College of Veterinary Medicine. Accepted July 1, 1992, $2,000. 
Hahn KA, Schuller HS, Legendre AM. B859-035 (Dexniguldipine) treatment of dogs with 
spontaneously occurring osteogenic sarcoma. Byk Gulden Pharmaceuticals, Hamburg, Germany. 
Accepted January 1, 1993, $63,890. 
Hahn KA. Promoting the responsible handling of anticancer drugs by veterinary personnel. The 
Minkel Grant Program, University of Tennessee. Accepted January 28, 1993, $2,300. 
Hahn KA. Use of SR-2508 in in vitro an in vivo clinical studies. National Cancer Institute. 
Accepted March 22, 1993. Drug support (Approximate value, $4,000). 
Hahn KA. Efficacy of SR-2508 as a radiosensitizer at low and high radiation doses. University 
of Tennesssee College of Veterinary Medicine Center of Excellence. Accepted July 1, 1993. 
$17 ,300. 
Hahn KA. Evaluation of cisp1atin toxicity modulation by etanidazole. Venture Grant Program, 
University of Tennessee College of Veterinary Medicine. Accepted July 1, 1993. $1,500. 
Frazier DL, Hahn KA. Cisplatin pharmacokinetics and clinical response in the dog. Supported, 
in part, by Bristol Laboratories (Approximate support, $35,000). 
Frazier DL, Hahn KA. Adriamycin pharmacokinetics and clinical response in the cat. 
Supported, in part, by Adria Laboratories (Approximate support, $35,000). 
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